Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Last Name

profileJorge Plutzky, M.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
AddressBrigham & Women's Hospital
Cardiovascular Medicine, NRB 742
77 Avenue Louis Pasteur
Boston MA 02115
Phone6175254360, 4361
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R56HL125894     (PLUTZKY, JORGE)Sep 8, 2015 - Aug 31, 2016
Epigenetic Control of Endothelial and T Cell States By BET Reader Proteins
Role: Principal Investigator

R01HL079117     (PLUTZKY, JORGE)Jan 1, 2005 - Dec 31, 2005
Endogenous Mechanisms of PPAR Modulation
Role: Principal Investigator

R01HL071745     (PLUTZKY, JORGE)Jan 1, 2004 - Dec 31, 2009
Lipolytic Mechanisms of PPAR Activation
Role: Principal Investigator

K08HL003107     (PLUTZKY, JORGE)Jul 1, 1994 - Jun 30, 1999
Role: Principal Investigator

P01HL048743     (MICHEL, THOMAS)Sep 30, 1992 - Mar 31, 2015
Arterial Dysfunction: Basic and Clinical Mechanisms
Role: Co-Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Carroll SH, Zhang E, Wang BF, LeClair KB, Rahman A, Cohen DE, Plutzky J, Patwari P, Lee RT. Correction: Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in ß-adrenergic receptor signaling. PLoS One. 2017; 12(7):e0181492. PMID: 28700749.
    View in: PubMed
  2. Carroll SH, Zhang E, Wang BF, LeClair KB, Rahman A, Cohen DE, Plutzky J, Patwari P, Lee RT. Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in ß-adrenergic receptor signaling. PLoS One. 2017; 12(3):e0173823. PMID: 28291835.
    View in: PubMed
  3. Zhang H, Plutzky J, Shubina M, Turchin A. Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. J Clin Lipidol. 2016 Nov - Dec; 10(6):1406-1413. PMID: 27919358.
    View in: PubMed
  4. Duan Q, Mao X, Liao C, Zhou H, Sun Z, Deng X, Hu Q, Qi J, Zhang G, Huang H, Plutzky J, Yang T. Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice. Int J Cardiol. 2016 Nov 15; 223:428-432. PMID: 27544600.
    View in: PubMed
  5. Keating ST, Plutzky J, El-Osta A. Epigenetic Changes in Diabetes and Cardiovascular Risk. Circ Res. 2016 May 27; 118(11):1706-22. PMID: 27230637.
    View in: PubMed
  6. Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PLoS One. 2016; 11(5):e0155228. PMID: 27148965; PMCID: PMC4858152.
  7. Liu Z, Xiao Y, Zhou Z, Mao X, Cai J, Xiong L, Liao C, Huang F, Liu Z, Ali Sheikh MS, Plutzky J, Huang H, Yang T, Duan Q. Extensive metabolic disorders are present in APC(min) tumorigenesis mice. Mol Cell Endocrinol. 2016 May 15; 427:57-64. PMID: 26948948.
    View in: PubMed
  8. Duan Q, Mao X, Xiao Y, Liu Z, Wang Y, Zhou H, Zhou Z, Cai J, Xia K, Zhu Q, Qi J, Huang H, Plutzky J, Yang T. Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. Biochim Biophys Acta. 2016 Apr; 1859(4):564-71. PMID: 26855180.
    View in: PubMed
  9. Kim SH, Plutzky J. Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. Diabetes Metab J. 2016 Feb; 40(1):12-21. PMID: 26912151; PMCID: PMC4768046.
  10. Milstone DS, Ilyama M, Chen M, O'Donnell P, Davis VM, Plutzky J, Brown JD, Haldar SM, Siu A, Lau AC, Zhu SN, Basheer MF, Collins T, Jongstra-Bilen J, Cybulsky MI. Differential role of an NF-?B transcriptional response element in endothelial versus intimal cell VCAM-1 expression. Circ Res. 2015 Jul 03; 117(2):166-77. PMID: 26034041; PMCID: PMC4758452.
  11. Rhee EJ, Park SE, Oh HG, Park CY, Oh KW, Park SW, Blankstein R, Plutzky J, Lee WY. Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort. Atherosclerosis. 2015 May; 240(1):242-9. PMID: 25818250.
    View in: PubMed
  12. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, Oh J, Zimmerman CO, Hwang J, Abbara S, Plutzky J, Robbins G, Tawakol A, Hoffmann U, Grinspoon SK. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015 Feb; 2(2):e52-63. PMID: 26424461; PMCID: PMC4820828.
  13. Plutzky J. Emerging epigenetic maps in atherosclerosis. Circ Cardiovasc Genet. 2014 Oct; 7(5):573-5. PMID: 25518042.
    View in: PubMed
  14. Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, Bair S, Newton G, Lichtman AH, Kung AL, Yang T, Wang H, Luscinskas FW, Croce KJ, Bradner JE, Plutzky J. NF-?B directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014 Oct 23; 56(2):219-31. PMID: 25263595; PMCID: PMC4224636.
  15. Pande RL, Brown J, Buck S, Redline W, Doyle J, Plutzky J, Creager MA. Association of monocyte tumor necrosis factor a expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. J Vasc Surg. 2015 Jan; 61(1):155-61. PMID: 25095746; PMCID: PMC4276540 [Available on 01/01/16].
  16. Halter JB, Musi N, McFarland Horne F, Crandall JP, Goldberg A, Harkless L, Hazzard WR, Huang ES, Kirkman MS, Plutzky J, Schmader KE, Zieman S, High KP. Diabetes and cardiovascular disease in older adults: current status and future directions. Diabetes. 2014 Aug; 63(8):2578-89. PMID: 25060886; PMCID: PMC4113072.
  17. Nallamshetty S, Le PT, Wang H, Issacsohn MJ, Reeder DJ, Rhee EJ, Kiefer FW, Brown JD, Rosen CJ, Plutzky J. Retinaldehyde dehydrogenase 1 deficiency inhibits PPAR?-mediated bone loss and marrow adiposity. Bone. 2014 Oct; 67:281-91. PMID: 25064526; PMCID: PMC4209126.
  18. Zhang H, Plutzky J, Turchin A. (Mis)interpreting studies on the adverse effects of statins. BMJ. 2014 Jun 11; 348:g3652. PMID: 24920686.
    View in: PubMed
  19. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoglu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014 Jan 24; 13:26. PMID: 24460800; PMCID: PMC3922777.
  20. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014 May-Jun; 28(3):399-405. PMID: 24561125; PMCID: PMC4231710.
  21. Liu S, Brown JD, Stanya KJ, Homan E, Leidl M, Inouye K, Bhargava P, Gangl MR, Dai L, Hatano B, Hotamisligil GS, Saghatelian A, Plutzky J, Lee CH. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature. 2013 Oct 24; 502(7472):550-4. PMID: 24153306; PMCID: PMC4141623.
  22. Chamarthi B, Zafrir B, Plutzky J, Givertz MM. Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. J Heart Lung Transplant. 2014 Feb; 33(2):215-7. PMID: 24315787; PMCID: PMC4231717.
  23. Nallamshetty S, Wang H, Rhee EJ, Kiefer FW, Brown JD, Lotinun S, Le P, Baron R, Rosen CJ, Plutzky J. Deficiency of retinaldehyde dehydrogenase 1 induces BMP2 and increases bone mass in vivo. PLoS One. 2013; 8(8):e71307. PMID: 23951127; PMCID: PMC3739807.
  24. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013 Aug 01; 154(3):569-82. PMID: 23911322; PMCID: PMC4090947.
  25. Zhang H, Plutzky J, Turchin A. Discontinuation of statins in routine care settings. Ann Intern Med. 2013 Jul 02; 159(1):75-6. PMID: 23817716.
    View in: PubMed
  26. Khera AV, Plutzky J. Management of low levels of high-density lipoprotein-cholesterol. Circulation. 2013 Jul 02; 128(1):72-8. PMID: 23817482; PMCID: PMC4231714.
  27. Tatematsu S, Francis SA, Natarajan P, Rader DJ, Saghatelian A, Brown JD, Michel T, Plutzky J. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb Vasc Biol. 2013 Aug; 33(8):1788-94. PMID: 23723371; PMCID: PMC3794714.
  28. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 02; 158(7):526-34. PMID: 23546564; PMCID: PMC3692286.
  29. Plutzky J, Garber A, Falahati A, Toft AD, Poulter NR. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. Can J Diabetes. 2009; 33(3):209-10. PMID: 25998594.
    View in: PubMed
  30. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J. 2012 Nov; 164(5):672-80. PMID: 23137497; PMCID: PMC4231713.
  31. Kiefer FW, Cohen P, Plutzky J. Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. Circulation. 2012 Aug 28; 126(9):1012-5. PMID: 22927471; PMCID: PMC3711937.
  32. de Ferranti SD, Daniels SR, Gillman M, Vernacchio L, Plutzky J, Baker AL. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood? Clin Chem. 2012 Dec; 58(12):1626-30. PMID: 22730451.
    View in: PubMed
  33. Rhee EJ, Plutzky J. Retinoid metabolism and diabetes mellitus. Diabetes Metab J. 2012 Jun; 36(3):167-80. PMID: 22737656; PMCID: PMC3380120.
  34. Kiefer FW, Vernochet C, O'Brien P, Spoerl S, Brown JD, Nallamshetty S, Zeyda M, Stulnig TM, Cohen DE, Kahn CR, Plutzky J. Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. Nat Med. 2012 Jun; 18(6):918-25. PMID: 22561685; PMCID: PMC3792792.
  35. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012 Jun; 205 Suppl 3:S368-74. PMID: 22577210; PMCID: PMC3349296.
  36. Elmasri H, Ghelfi E, Yu CW, Traphagen S, Cernadas M, Cao H, Shi GP, Plutzky J, Sahin M, Hotamisligil G, Cataltepe S. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis. 2012 Sep; 15(3):457-68. PMID: 22562362; PMCID: PMC3590918.
  37. Kiefer FW, Orasanu G, Nallamshetty S, Brown JD, Wang H, Luger P, Qi NR, Burant CF, Duester G, Plutzky J. Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. Endocrinology. 2012 Jul; 153(7):3089-99. PMID: 22555438; PMCID: PMC3380298.
  38. Jain M, Plutzky J. Commentary. Clin Chem. 2012 May; 58(5):829-30. PMID: 22544857.
    View in: PubMed
  39. Plutzky J. The incretin axis in cardiovascular disease. Circulation. 2011 Nov 22; 124(21):2285-9. PMID: 22105195.
    View in: PubMed
  40. Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan; 153(1):113-22. PMID: 22045665; PMCID: PMC3249680.
  41. Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA Annu Symp Proc. 2011; 2011:1270-9. PMID: 22195188; PMCID: PMC3243255.
  42. Shabrova EV, Tarnopolsky O, Singh AP, Plutzky J, Vorsa N, Quadro L. Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice. PLoS One. 2011; 6(10):e24634. PMID: 22016761; PMCID: PMC3189911.
  43. Blaser BW, Kim HT, Alyea EP, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83. PMID: 21839706; PMCID: PMC3805283.
  44. Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):25B-32B. PMID: 21802578.
    View in: PubMed
  45. Davidson MH, Plutzky J. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):1B-2B. PMID: 21802576.
    View in: PubMed
  46. Rhee EJ, Nallamshetty S, Plutzky J. Retinoid metabolism and its effects on the vasculature. Biochim Biophys Acta. 2012 Jan; 1821(1):230-40. PMID: 21810483.
    View in: PubMed
  47. Brown JD, Oligino E, Rader DJ, Saghatelian A, Plutzky J. VLDL hydrolysis by hepatic lipase regulates PPARd transcriptional responses. PLoS One. 2011; 6(7):e21209. PMID: 21750705; PMCID: PMC3130023.
  48. Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011 Jun 12; 17(7):812-5. PMID: 21666694; PMCID: PMC3374483.
  49. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011 Aug; 54(8):2132-42. PMID: 21562757; PMCID: PMC3131508.
  50. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011 Apr 15; 108(8):1002-16. PMID: 21493923.
    View in: PubMed
  51. Chang K, Francis SA, Aikawa E, Figueiredo JL, Kohler RH, McCarthy JR, Weissleder R, Plutzky J, Jaffer FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010 Oct; 30(10):1933-9. PMID: 20689078; PMCID: PMC3030475.
  52. Fonseca VA, Zinman B, Nauck MA, Goldfine AB, Plutzky J. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med. 2010 Jul; 123(7):S2-S10. PMID: 20609666.
    View in: PubMed
  53. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, Krauss RM. VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res. 2010 Aug; 51(8):2275-81. PMID: 20421589; PMCID: PMC2903797.
  54. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes. 2010 Jun; 59(6):1424-34. PMID: 20299477; PMCID: PMC2874703.
  55. Brown J, Nallamshetty S, Plutzky J. Intersecting vectors of basic science research and clinical medicine: LOX-1? Clin Chem. 2010 Apr; 56(4):499-501. PMID: 20185618.
    View in: PubMed
  56. Plutzky J. Expansion and contraction: the mighty, mighty fatty acid. Nat Med. 2009 Jun; 15(6):618-9. PMID: 19498375.
    View in: PubMed
  57. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009 Feb 03; 53(5 Suppl):S35-42. PMID: 19179216; PMCID: PMC2663393.
  58. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T, Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest. 2009 Jan; 119(1):110-24. PMID: 19065047.
    View in: PubMed
  59. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008 Nov 17; 102(10 Suppl):1K-34K. PMID: 19068318.
    View in: PubMed
  60. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov; 5(4):319-35. PMID: 18958843.
    View in: PubMed
  61. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008 Sep 02; 52(10):869-81. PMID: 18755353; PMCID: PMC2633943.
  62. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008 May 24; 371(9626):1800-9. PMID: 18502305; PMCID: PMC2774464.
  63. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008 Jun 13; 283(24):16477-87. PMID: 18411276; PMCID: PMC2423236.
  64. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol. 2008 Jan; 19(1):4-7. PMID: 18178795.
    View in: PubMed
  65. Plutzky J. A cardiologist's perspective on cardiometabolic risk. Am J Cardiol. 2007 Dec 17; 100(12A):3P-6P. PMID: 18154744.
    View in: PubMed
  66. Ziouzenkova O, Plutzky J. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008 Jan 09; 582(1):32-8. PMID: 18068127.
    View in: PubMed
  67. Plutzky J. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha. Diab Vasc Dis Res. 2007 Sep; 4 Suppl 3:S12-4. PMID: 17935055.
    View in: PubMed
  68. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med. 2007 Aug; 262(2):184-98. PMID: 17645586.
    View in: PubMed
  69. Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J, Hamilton JA, Tang G, Dolnikowski GG, Vogel S, Duester G, Plutzky J. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med. 2007 Jun; 13(6):695-702. PMID: 17529981; PMCID: PMC2233696.
  70. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007 Aug; 1771(8):972-82. PMID: 17631413; PMCID: PMC2083576.
  71. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007 Jan 30; 115(4):518-33. PMID: 17261671.
    View in: PubMed
  72. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72. PMID: 17192355.
    View in: PubMed
  73. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 02; 115(1):114-26. PMID: 17192512.
    View in: PubMed
  74. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol. 2007 Feb 19; 99(4A):27B-40B. PMID: 17307056.
    View in: PubMed
  75. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006 Dec 19; 114(25):2871-91. PMID: 17179035.
    View in: PubMed
  76. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19; 114(25):2850-70. PMID: 17179034.
    View in: PubMed
  77. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006 Dec; 58(4):726-41. PMID: 17132851.
    View in: PubMed
  78. Ziouzenkova O, Orasanu G, Sukhova G, Lau E, Berger JP, Tang G, Krinsky NI, Dolnikowski GG, Plutzky J. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol. 2007 Jan; 21(1):77-88. PMID: 17008383.
    View in: PubMed
  79. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol. 2006 Aug; 26(8):1806-13. PMID: 16709944.
    View in: PubMed
  80. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 03; 98(4):490-8. PMID: 16439686; PMCID: PMC4231787.
  81. Lee CH, Plutzky J. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? Circulation. 2006 Jan 03; 113(1):5-8. PMID: 16391165.
    View in: PubMed
  82. Oligino E, Ziouzenkova O, Plutzky J. . VLDL hydrolysis by hepatic lipase is a distinct mechanism for PPAR-delta activation. Sarnoff Endowment, Washington, DC. 2006.
  83. Gornik HL, Plutzky J. . Dyslipidemia. In: Gaziano JM, editor. Atlas of Cardiovascular Risk Factors. 2005; 97-114.
  84. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care. 2005 May; 28(5):1145-50. PMID: 15855580; PMCID: PMC4231709.
  85. Plutzky J, Ziouzenkova O. . Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions. 2005.
  86. Orasanu G, Ziouzenkova O, Plutzky J. . Peroxisome proliferator activated receptors (PPARs) – potential targets for diabetic atherosclerosis. In: Cheta D, editor. Vascular Involvement in Diabetes. 2005; 35-49.
  87. Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2):147-73. PMID: 18370723.
    View in: PubMed
  88. Plutzky J. . Peroxisome proliferator-activated receptors in diabetes, vascular inflammation, and atherosclerosis (DVD, audio tape). 2005.
  89. Devchand PR, Ziouzenkova O, Plutzky J. Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? Circ Res. 2004 Dec 10; 95(12):1137-9. PMID: 15591235.
    View in: PubMed
  90. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord. 2004 Aug; 5(3):255-9. PMID: 15211097.
    View in: PubMed
  91. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care. 2004 Jul; 7(4):369-75. PMID: 15192437.
    View in: PubMed
  92. Plutzky J. PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction. Clin Cardiol. 2004 Jul; 27(7 Suppl 4):IV1-2. PMID: 15470904.
    View in: PubMed
  93. Ahmed W, Ziouzenkova O, Orasanu G, Marchadier D, Rader D, Plutzky J. . Endothelial lipase acts on HDL to activate PPAR?. American Heart Association Scientific Sessions, New Orleans, LA. 2004.
  94. Ziouzenkova O, Plutzky J. . Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis. International Congress Series. 2004; 1262:147-151.
  95. Orasanu G, Ziouzenkova O, Ahmed W, Shoelson S, Plutzky J. Lipoprotein metabolism and uptake direct divergent peroxisome proliferator-activated receptor-? and hepatocyte nuclear factor 4? responses. American Heart Association Scientific Sessions, New Orleans, LA. 2004.
  96. Plutzky J. The vascular biology of atherosclerosis. Am J Med. 2003 Dec 08; 115 Suppl 8A:55S-61S. PMID: 14678867.
    View in: PubMed
  97. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J Am Coll Cardiol. 2003 Nov 19; 42(10):1764-6. PMID: 14642685.
    View in: PubMed
  98. Beckman J, Raji A, Plutzky J. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr Opin Cardiol. 2003 Nov; 18(6):479-85. PMID: 14597889.
    View in: PubMed
  99. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology? Science. 2003 Oct 17; 302(5644):406-7. PMID: 14563997.
    View in: PubMed
  100. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003 Aug 18; 92(4A):34J-41J. PMID: 12957325.
    View in: PubMed
  101. Ziouzenkova O, Asatryan L, Sahady D, Orasanu G, Perrey S, Cutak B, Hassell T, Akiyama TE, Berger JP, Sevanian A, Plutzky J. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem. 2003 Oct 10; 278(41):39874-81. PMID: 12878589; PMCID: PMC4231711.
  102. Plutzky J. . PPARs and atherosclerosis. In: Duttaroy AK, Spener F, editors. Cellular proteins and their fatty acids in health and disease. 2003; Chapter 23.
  103. Plutzky J. Diabetes as a vascular disease. Dyslipidemia as a target. Postgrad Med. 2003 Apr; 113(4 Suppl):15-23. PMID: 19667619.
    View in: PubMed
  104. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003 May 01; 23(5):859-63. PMID: 12663371; PMCID: PMC4231712.
  105. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2730-5. PMID: 12606719; PMCID: PMC151409.
  106. Kramer D, Raji A, Plutzky J. Prediabetes mellitus and its links to atherosclerosis. Curr Diab Rep. 2003 Feb; 3(1):11-8. PMID: 12643141.
    View in: PubMed
  107. Plutzky J, Libby P. . Pathophysiology of atherosclerotic heart disease. In: Tonkin AM, editor. Atherosclerosis and Heart Disease. 2003; 1-12.
  108. Plutzky J. . PPARs. In: Izzo JL, Black HR, editors. Hypertension Primer. 2003; 60-62.
  109. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002 Nov 26; 106(22):2760-3. PMID: 12450998.
    View in: PubMed
  110. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications. 2002 Nov-Dec; 16(6):401-15. PMID: 12477625.
    View in: PubMed
  111. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep. 2002 Nov; 4(6):514-21. PMID: 12379175.
    View in: PubMed
  112. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood. 2002 Aug 15; 100(4):1340-6. PMID: 12149216.
    View in: PubMed
  113. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002 Apr 05; 90(6):703-10. PMID: 11934839; PMCID: PMC4231718.
  114. Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep. 2002 Jan; 4(1):59-64. PMID: 11772424.
    View in: PubMed
  115. Plutzky J, Libby P. . Diabetes and cardiovascular disease (DVD). 2002.
  116. Plutzky J. . The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease. Am J Cardiol. 2002; 90(7 ): 139-143.
  117. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001 Oct 18; 88(8A):10K-15K. PMID: 11694213.
    View in: PubMed
  118. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol. 2001 Oct; 12(5):511-8. PMID: 11561170.
    View in: PubMed
  119. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001 Aug; 8(4):203-10. PMID: 11550998.
    View in: PubMed
  120. Plutzky J, Davidson J. . Diabetes and cardiovascular disease in the Hispanic population, (CD-ROM). 2001.
  121. Plutzky J, Ridker PM. Statins for stroke: the second story? Circulation. 2001 Jan 23; 103(3):348-50. PMID: 11157683.
    View in: PubMed
  122. Marx N, Mackman N, Schönbeck U, Yilmaz N, Hombach V, Libby P, Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001 Jan 16; 103(2):213-9. PMID: 11208679.
    View in: PubMed
  123. Plutzky J. . PPARs and diabetic atherosclerosis. 2001.
  124. Plutzky J. . Insulin resistance and atherosclerosis. 2001.
  125. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000 Nov; 15(6):416-21. PMID: 11198624.
    View in: PubMed
  126. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000 Jul; 2(4):327-35. PMID: 11122762.
    View in: PubMed
  127. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000 Jun 15; 164(12):6503-8. PMID: 10843708; PMCID: PMC4231715.
  128. Plutzky J. . PPARs and diabetic atherosclerosis. 2000.
  129. Plutzky J. . Atherosclerosis: an insulin resistance disorder. Proceedings from the Second Annual US/Japanese Dialogue on Lipids and Atherosclerosis. 2000; 245:49-58.
  130. Plutzky J, Libby P, Nakamura H. Second annual US/Japanese dialogue on lipids and atherosclerosis: towards an understanding of mechanism. 2000.
  131. Libby P, Aikawa M, Schoenbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. In: Stemme S, Olsson AG, editors. Atherosclerosis XII. 2000; 67-80.
  132. Libby P, Aikawa M, Schönbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. 2000.
  133. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999 Oct; 6(5):337-46. PMID: 10534139.
    View in: PubMed
  134. Kinlay S, Plutzky J. Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep. 1999 Sep; 1(3):238-43. PMID: 10980848.
    View in: PubMed
  135. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol. 1999 Jul 08; 84(1A):15J-20J. PMID: 10418853.
    View in: PubMed
  136. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999 Jun 22; 99(24):3125-31. PMID: 10377075; PMCID: PMC4231776.
  137. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999 Mar; 19(3):546-51. PMID: 10073956.
    View in: PubMed
  138. Plutzky J. . Making sense of clinical trials in lipid lowering. Intensive review of internal medicine (CD-ROM). 1999.
  139. Plutzky J. . Coronary artery disease in the younger patient. New issues for the next millennium. 1999; 238:75-83.
  140. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998 Nov 30; 83(11):1097-103. PMID: 9831704; PMCID: PMC4231720.
  141. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998 Jul; 153(1):17-23. PMID: 9665460; PMCID: PMC1852950.
  142. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35. PMID: 9537338.
    View in: PubMed
  143. Plutzky J. . Myocardial infarction in the younger patient. Cannon CP, editor. Management of acute coronary syndrome. 1998; 653-666. .
  144. Plutzky J. . Disorders of the heart and vascular system. Harrison’s Principles of Internal Medicine Self-Assessment and Review. 1998; 49-90. .
  145. Blumnethal RS, Plutzky J. Secondary prevention of myocardial infarction. Cannon CP, editor. Management of acute coronary syndrome. 1998; 695-704.
  146. Oberg K, Cannon C, Plutzky J. Focus on reteplase: a newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45.
  147. Freeman R, Plutzky J, Neel B, Rosenberg R. Methods for identifying a tyrosine phosphatase abnormally associated with neoplastic disease. 1996.
  148. Neel BG, Plutzky J, Rosenberg RD, Freeman RM, Lorenz U, Lechleider RJ. . Molecular cloning and characterization of a subfamily of nontransmembrane PTPs containing src homology 2 (SH2) domains. Adv Protein Phosphatases. 1993; 7:127-151.
  149. Freeman RM, Plutzky J, Neel BG. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A. 1992 Dec 01; 89(23):11239-43. PMID: 1280823; PMCID: PMC50525.
  150. Plutzky J, Neel BG, Rosenberg RD, Eddy RL, Byers MG, Jani-Sait S, Shows TB. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics. 1992 Jul; 13(3):869-72. PMID: 1639416.
    View in: PubMed
  151. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992 Feb 01; 89(3):1123-7. PMID: 1736296; PMCID: PMC48398.
  152. Plutzky J. On being a physician. Am J Med. 1990 Aug; 89(2):252. PMID: 2382677.
    View in: PubMed
  153. Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A. 1986 Feb; 83(3):546-50. PMID: 3511471; PMCID: PMC322900.
  154. Beckmann RJ, Schmidt RJ, Santerre RF, Plutzky J, Crabtree GR, Long GL. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res. 1985 Jul 25; 13(14):5233-47. PMID: 2991859; PMCID: PMC321861.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at For faculty personal and demographic information, contact HMS Office for Faculty Affairs at
Plutzky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
Co-Authors Expand Description
Similar People Expand Description
Same Department Expand Description
Physical Neighbors Expand Description